Elutia

Elutia Inc. is a biotechnology company focused on developing and commercializing drug-eluting biomatrix products that enhance the compatibility of medical devices with patients. The company aims to "Humanize Medicine so Patients can Thrive without Compromise" by addressing post-surgical complications associated with medical device implants. Elutia's flagship product, EluPro™, is the first FDA-approved antibiotic-eluting biologic envelope, designed to reduce infections and improve patient outcomes for those receiving implantable medical devices. The company has successfully completed FDA inspections of its manufacturing facility and has begun commercial production of EluPro. Headquartered in Maryland, Elutia operates in the regenerative medicine and medical device compatibility sectors, targeting healthcare providers and patients. Since its strategic rebranding in September 2023, the company has seen significant growth, including a 20% increase in proprietary product sales. Elutia employs between 11 and 50 people and is committed to delivering innovative solutions that enhance the safety and efficacy of medical device implants.

• Employees 51
• Founded 2014
• Annual Revenue $23711000
• Total Funding $107000000